Author

D. R. Liu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Bioengineering· 1 Cell Biology· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 6 Approach:experimental assay· 5 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Organism:bacteria (other)· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1

Frequent Co-Authors

A. Choudhary· 2 shared B. L. Ebert· 2 shared J. A. M. Mercer· 2 shared M. Jan· 2 shared V. Sreekanth· 2 shared A. Abraham· 1 shared A. Bera· 1 shared A. Deb· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

A. Choudhary

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Small-molecule binding and sensing with a designed protein family

G. R. Lee, S. J. Pellock, C. Norn, D. Tischer, J. Dauparas, I. Anishchenko, J. A. M. Mercer, A. Kang, A. Bera, H. Nguyen, I. Goreshnik, D. Vafeados, N. Roullier, H. L. Han, B. Coventry, , D. Baker

This paper designs a protein family that binds and senses small molecules using deep learning and physics-based methods, achieving nanomolar sensitivity for cortisol.

bioRxiv · Nov 1, 2023Biochemistry

A molecular glue approach to control the half-life of CRISPR-based technologies

V. Sreekanth, M. Jan, K. T. Zhao, D. Lim, J. R. Davis, M. McConkey, V. Kovalcik, S. Barkal, B. K. Law, J. Fife, R. Tian, M. E. Vinyard, B. Becerra, M. E. Kampmann, R. I. Sherwood, , A. Choudhary

This paper introduces a molecular glue approach using pomalidomide to control the half-life of CRISPR-based technologies, enabling precise regulation of their activity and therapeutic potential.

bioRxiv · Mar 12, 2023Bioengineering

Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene Therapy

F. Borot, O. Humbert, G. A. Newby, E. Fields, S. Kohli, S. Radtke, G. S. Laszlo, T. Mayuranathan, A. M. Ali, M. J. Weiss, J. S. Yen, R. B. Walter, D. R. Liu, S. Mukherjee, H.-P. Kiem

The paper develops a base editing approach to reduce on-target toxicity in CD33-directed therapies by editing CD33 and gamma globin genes in hematopoietic stem and progenitor cells.

bioRxiv · Feb 23, 2023 · PreprintCell Biology

Purified cytosolic crystals from Bacillus thuringiensis as a novel active pharmaceutical ingredient (API)

J. Chicca, N. R. Cazeault, F. Rus, A. Abraham, C. Garceau, H. Li, S. M. Atwa, K. Flanagan, E. Soto, M. S. Morrison, D. Gazzola, Y. Hu, D. R. Liu, M. K. Nielsen, J. F. Urban, , R. V. Aroian

This paper describes the scalable purification of Bt Cry5B crystals and demonstrates their potent bioactivity against nematodes in vitro and in vivo.

bioRxiv · May 20, 2022 · PreprintMicrobiology

Proteolysis Targeting Chimeras With Reduced Off-targets

T. M. Nguyen, V. Sreekanth, A. Deb, P. Kokkonda, P. K. Tiwari, K. A. Donovan, V. M. Shoba, S. K. Chaudhary, J. A. M. Mercer, S. Lai, A. Sadagopan, M. Jan, E. S. Fischer, D. R. Liu, B. L. Ebert, A. Choudhary

This study develops a platform to identify off-target degradation of ZF proteins by PROTACs and identifies design rules to reduce off-target effects using pomalidomide analogs.

bioRxiv · Nov 18, 2021Pharmacology & Toxicology

Multimodal small-molecule screening for human prion protein binders

A. G. Reidenbach, M. F. Mesleh, D. Casalena, S. M. Vallabh, J. L. Dahlin, A. J. Leed, A. I. Chan, D. L. Usanov, J. B. Yehl, C. T. Lemke, A. J. Campbell, R. N. Shah, O. K. Shrestha, J. R. Sacher, V. L. Rangel, , E. V. Minikel

This study screens for small-molecule binders of the human prion protein using multiple methods but finds only a weak binder with no therapeutic potential.

bioRxiv · Jun 18, 2020Biochemistry